Giovanni Latella1, Florian Rieder. 1. aGastroenterology Unit, Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy bDepartment of Gastroenterology, Hepatology and Nutrition, Digestive Disease and Surgery Institute cDepartment of Pathobiology, The Cleveland Clinic Foundation Lerner Research Institute, Cleveland, Ohio, USA.
Abstract
PURPOSE OF REVIEW: Intestinal fibrosis is a common complication of several enteropathies, with inflammatory bowel disease (IBD) being the major cause. Intestinal fibrosis affects both ulcerative colitis and Crohn's disease, and no specific antifibrotic therapy exists. This review highlights recent developments in this area. RECENT FINDINGS: The pathophysiology of intestinal stricture formation includes inflammation-dependent and inflammation-independent mechanisms. A better understanding of the mechanisms of intestinal fibrogenesis and the availability of compounds for other nonintestinal fibrotic diseases bring clincial trials in stricturing Crohn's disease within reach. SUMMARY: Improved understanding of its mechanisms and ongoing development of clinical trial endpoints for intestinal fibrosis will allow the testing of novel antifibrotic compounds in IBD.
PURPOSE OF REVIEW: Intestinal fibrosis is a common complication of several enteropathies, with inflammatory bowel disease (IBD) being the major cause. Intestinal fibrosis affects both ulcerative colitis and Crohn's disease, and no specific antifibrotic therapy exists. This review highlights recent developments in this area. RECENT FINDINGS: The pathophysiology of intestinal stricture formation includes inflammation-dependent and inflammation-independent mechanisms. A better understanding of the mechanisms of intestinal fibrogenesis and the availability of compounds for other nonintestinal fibrotic diseases bring clincial trials in stricturing Crohn's disease within reach. SUMMARY: Improved understanding of its mechanisms and ongoing development of clinical trial endpoints for intestinal fibrosis will allow the testing of novel antifibrotic compounds in IBD.
Authors: Daniel C Baumgart; Hans P Müller; Ulrike Grittner; Diana Metzke; Andreas Fischer; Olaf Guckelberger; Andreas Pascher; Ingolf Sack; Michael Vieth; Birgit Rudolph Journal: Radiology Date: 2015-02-06 Impact factor: 11.105
Authors: Magdalena Mazagova; Lirui Wang; Andrew T Anfora; Max Wissmueller; Scott A Lesley; Yukiko Miyamoto; Lars Eckmann; Suraj Dhungana; Wimal Pathmasiri; Susan Sumner; Caroline Westwater; David A Brenner; Bernd Schnabl Journal: FASEB J Date: 2014-12-02 Impact factor: 5.191
Authors: Florian Rieder; Giovanni Latella; Fernando Magro; Elif S Yuksel; Peter D R Higgins; Antonio Di Sabatino; Jessica R de Bruyn; Jordi Rimola; Jorge Brito; Dominik Bettenworth; Gert van Assche; Willem Bemelman; Andre d'Hoore; Gianluca Pellino; Axel U Dignass Journal: J Crohns Colitis Date: 2016-02-29 Impact factor: 9.071
Authors: Steve S Choi; Jason K Sicklick; Qi Ma; Liu Yang; Jiawen Huang; Yi Qi; Wei Chen; Yin-Xiong Li; Pascal J Goldschmidt-Clermont; Anna Mae Diehl Journal: Hepatology Date: 2006-11 Impact factor: 17.425
Authors: Patrick Marcellin; Edward Gane; Maria Buti; Nezam Afdhal; William Sievert; Ira M Jacobson; Mary Kay Washington; George Germanidis; John F Flaherty; Raul Aguilar Schall; Jeffrey D Bornstein; Kathryn M Kitrinos; G Mani Subramanian; John G McHutchison; E Jenny Heathcote Journal: Lancet Date: 2012-12-10 Impact factor: 79.321
Authors: Laura A Johnson; Eva S Rodansky; Andrew J Haak; Scott D Larsen; Richard R Neubig; Peter D R Higgins Journal: Inflamm Bowel Dis Date: 2014-01 Impact factor: 5.325
Authors: Talmadge E King; Williamson Z Bradford; Socorro Castro-Bernardini; Elizabeth A Fagan; Ian Glaspole; Marilyn K Glassberg; Eduard Gorina; Peter M Hopkins; David Kardatzke; Lisa Lancaster; David J Lederer; Steven D Nathan; Carlos A Pereira; Steven A Sahn; Robert Sussman; Jeffrey J Swigris; Paul W Noble Journal: N Engl J Med Date: 2014-05-18 Impact factor: 91.245
Authors: Ilyssa O Gordon; Suha Abushamma; Jacob A Kurowski; Stefan D Holubar; Lei Kou; Ruishen Lyu; Florian Rieder Journal: J Crohns Colitis Date: 2022-06-24 Impact factor: 10.020
Authors: Michael Elias; Shuai Zhao; Hongnga T Le; Jie Wang; Markus F Neurath; Clemens Neufert; Claudio Fiocchi; Florian Rieder Journal: J Clin Invest Date: 2021-01-19 Impact factor: 14.808